TOKYO — U.S. proxy advisory firm Institutional Shareholder Services (ISS) is recommending shareholders vote against the reelection of Takeda Pharmaceuticals CEO Christophe Weber to the Japanese drugmaker’s board, according to Takeda.
Takeda does not support the recommendation, and it is calling on shareholders to vote in favor of all proposals made by the company at the annual general meeting on June 25.
